Board members of Scandinavian ChemoTech fully subscribe to the current issue

Report this content

Members of Scandinavian ChemoTech's board have chosen to fully subscribe to the ongoing rights issue. These subscription commitments are in addition to previously communicated commitments and the subscription made by the Company's major owner and CEO Mohan Frick and his family of approximately SEK 2 million.

Through these subscription commitments, the board once again shows its trust and foundational faith in Scandinavian ChemoTech and the Company's future prospects.


For more information, please contact:

Mohan Frick, CEO


+46 (0)10-218 93 00



Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail:


Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: